Torrey Pines Therapeutics Licenses Three Drugs to Cenomed

10/8/08Follow @xconomy

Torrey Pines Therapeutics said today that it has sold worldwide rights for three drug candidates to Cenomed Biosciences, a subsidiary of Abraxis Bioscience. Cenomed, based in Irvine, CA, will get rights to phenserine, Posiphen, and bisnorcymcerine for chemical defense and biodefense. La Jolla, CA-based Torrey Pines (NASDAQ: TPTX) stands to receive milestone and royalty payments from progress made with the compounds.

By posting a comment, you agree to our terms and conditions.